PT  - JOURNAL ARTICLE
AU  - Bejan, Cosmin A.
AU  - Cahill, Katherine N.
AU  - Staso, Patrick J.
AU  - Choi, Leena
AU  - Peterson, Josh F.
AU  - Phillips, Elizabeth J.
TI  - DrugWAS: Leveraging drug-wide association studies to facilitate drug repurposing for COVID-19
AID  - 10.1101/2021.02.04.21251169
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.02.04.21251169
4099  - http://medrxiv.org/content/early/2021/02/08/2021.02.04.21251169.short
4100  - http://medrxiv.org/content/early/2021/02/08/2021.02.04.21251169.full
AB  - Importance There is an unprecedented need to rapidly identify safe and effective treatments for the novel coronavirus disease 2019 (COVID-19).Objective To systematically investigate if any of the available drugs in Electronic Health Record (EHR), including prescription drugs and dietary supplements, can be repurposed as potential treatment for COVID-19.Design, Setting, and Participants Based on a retrospective cohort analysis of EHR data, drug-wide association studies (DrugWAS) were performed on COVID-19 patients at Vanderbilt University Medical Center (VUMC). For each drug study, multivariable logistic regression with overlap weighting using propensity score was applied to estimate the effect of drug exposure on COVID-19 disease outcomes.Exposures Patient exposure to a drug during 1-year prior to the pandemic and COVID-19 diagnosis was chosen as exposure of interest. Natural language processing was employed to extract drug information from clinical notes, in addition to the prescription drug data available in structured format.Main Outcomes and Measures All-cause of death was selected as primary outcome. Hospitalization, admission to the intensive care unit (ICU), and need for mechanical ventilation were identified as secondary outcomes.Results The study included 7,768 COVID-19 patients, of which 509 (6.55%) were hospitalized, 82 (1.06%) were admitted to ICU, 64 (0.82%) received mechanical ventilation, and 90 (1.16%) died. Overall, 15 drugs were significantly associated with decreased COVID-19 severity. Previous exposure to either Streptococcus pneumoniae vaccines (adjusted odds ratio [OR], 0.38; 95% CI, 0.14-0.98), diphtheria toxoid vaccine (OR, 0.39; 95% CI, 0.15-0.98), and tetanus toxoid vaccine (OR, 0.39; 95% CI, 0.15-0.98) were significantly associated with a decreased risk of death (primary outcome). Secondary analyses identified several other significant associations showing lower risk for COVID-19 outcomes: 2 vaccines (acellular pertussis, Streptococcus pneumoniae), 3 dietary supplements (turmeric extract, flaxseed extract, omega-3 fatty acids), methylprednisolone acetate, pseudoephedrine, ethinyl estradiol, estradiol, ibuprofen, and fluticasone.Conclusions and Relevance This cohort study leveraged EHR data to identify a list of drugs that could be repurposed to improve COVID-19 outcomes. Further randomized clinical trials are needed to investigate the efficacy of the proposed drugs.Question Can Electronic Health Records (EHRs) be used to search for drug candidates that could be repurposed to treat the coronavirus disease 2019 (COVID-19)?Findings Drug-wide association studies (DrugWAS) of COVID-19 severity outcomes were conducted on a cohort of 7,768 COVID-19 patients. The study found 15 drug ingredients that are significantly associated with a decreased risk of death and other severe COVID-19 outcomes.Meaning The list of drugs proposed by this study could provide additional insights into developing new candidates for COVID-19 treatment.Competing Interest StatementDr Cahill reported personal fees from Teva, personal fees from Optinose, personal fees from Novartis, personal fees from GlaxoSmithKline, personal fees from Blueprint Medicines, personal fees from Third Harmonic Bio, personal fees from Sanofi Pasteur, personal fees from Genentech, and personal fees from Regeneron, outside the submitted work. Dr Peterson reported personal fees from Color Genomics outside the submitted work. Dr Phillips receives Royalties from Uptodate and consulting fees from Janssen, Vertex, Biocryst and Regeneron outside of the submitted work. She is co-director of IIID Pty Ltd that holds a patent for HLA-B*57:01 testing for abacavir hypersensitivity, and has a patent pending for Detection of Human Leukocyte Antigen-A*32:01 in connection with Diagnosing Drug Reaction with Eosinophilia and Systemic Symptoms without any financial remuneration and not directly related to the submitted work. No other disclosures were reported.Funding StatementThis work was supported by NIH grants P50GM115305, R01HG010863, R01AI150295, K23AI118804, and UL1TR000445. The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Vanderbilt University Medical Center IRB #201552 approval letter --RE: IRB #201552 “Medication-wide association studies (MedWAS) of COVID-19 diagnosis and severity”Dear Cosmin Adrian Bejan:A designee of the Institutional Review Board reviewed the Request for Exemption application identified above. It was determined the study poses minimal risk to participants. This study meets 45 CFR 46.104 (d) category (4)(iii) for Exempt Review.Any changes to this proposal that may alter its exempt status should be presented to the IRB for approval prior to implementation of the changes.DATE OF IRB APPROVAL: 8/12/2020All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData contain protected health information and are not publicly available. The summary statistics extracted from the EHR data used in this study are provided in the manuscript and supplementary material.